Zero COVID-19 infection in inflammatory bowel disease patients: Findings from population-based inflammatory bowel disease registries in Hong Kong and Taiwan.
J Gastroenterol Hepatol
; 36(1): 171-173, 2021 Jan.
Article
in English
| MEDLINE | ID: covidwho-1032414
ABSTRACT
BACKGROUND AND AIM:
It is unsure whether inflammatory bowel disease (IBD) is a risk factor for novel coronavirus infection (COVID-19).METHODS:
IBD patients were identified from population-based databases in Hong Kong and Taiwan from January 21, 2020, until April 15, 2020.RESULTS:
Total 2954 and 2554 IBD patients were identified in Hong Kong and Taiwan, respectively. None had COVID-19. Pooled analysis showed that 65.3%, 39.1%, 4.3%, and 12.8% IBD patients in Hong Kong and 75.8 %, 51.4 %, 26.1%, and 52.3 % in Taiwan were on 5-aminosalicylates, immunomodulators, corticosteroids, and biologics, respectively.CONCLUSION:
There were no reported cases of COVID-19 infection amongst IBD patients in Hong Kong and Taiwan. IBD patients should continue their usual medications during the COVID-19 pandemic.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Inflammatory Bowel Diseases
/
COVID-19
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
/
Reviews
Topics:
Long Covid
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Asia
Language:
English
Journal:
J Gastroenterol Hepatol
Journal subject:
Gastroenterology
Year:
2021
Document Type:
Article
Affiliation country:
Jgh.15164
Similar
MEDLINE
...
LILACS
LIS